VASKA, A., M. MAKOHUSOVA, Karla PLEVOVÁ, K. SKALICKA, M. CERMAK, F. CHOVANEC, O. FABRI, P. SVEC and A. KOLENOVA. Clinical impact of genomic analysis in children with B-acute lymphoblastic leukemia: A pilot study in Slovakia. Neoplasma. Bratislava: Slovenská akademie vied, 2019, vol. 66, No 6, p. 1009-1018. ISSN 0028-2685. Available from: https://dx.doi.org/10.4149/neo_2019_190328N274.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Clinical impact of genomic analysis in children with B-acute lymphoblastic leukemia: A pilot study in Slovakia
Authors VASKA, A. (703 Slovakia), M. MAKOHUSOVA (703 Slovakia), Karla PLEVOVÁ (203 Czech Republic, guarantor, belonging to the institution), K. SKALICKA (703 Slovakia), M. CERMAK (703 Slovakia), F. CHOVANEC (703 Slovakia), O. FABRI (703 Slovakia), P. SVEC (703 Slovakia) and A. KOLENOVA (703 Slovakia).
Edition Neoplasma, Bratislava, Slovenská akademie vied, 2019, 0028-2685.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher Slovakia
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 1.721
RIV identification code RIV/00216224:14110/19:00112733
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.4149/neo_2019_190328N274
UT WoS 000499649200017
Keywords in English children acute lymphoblastic leukemia; B-other; genetic markers; SNP-array
Tags 14110212, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Pavla Foltynová, Ph.D., učo 106624. Changed: 31/3/2020 22:12.
Abstract
Acute lymphoblastic leukemia (ALL) belongs to a genetically heterogeneous disease associated with a wide range of chromosomal and molecular changes. Determining these changes at the time of diagnosis can help the therapeutic decision, and contributes to the prediction of patients' clinical outcomes. A part of B-ALL (B-other) lacks cytogenetic abnormalities with clinical relevance for prognosis. Our first goal was to retrospectively review genetic results of patients from 2013-2017 and identify number of B-other patients in Slovak population. The second goal was to implement single nucleotide polymorphism (SNP) array analysis to improve the diagnosis and risk stratification. In this study we reviewed 133 B-ALL patients. We found that nearly 40% of them (52 cases) belonged to the B-other ALL group. Eighteen B-other ALL patients were subjected to the analysis using SNP-array. Overall, we identified 126 cytogenomic changes and in 4 patients the SNP array revealed clinically relevant markers of adverse prognosis and high relapse risk. Integrating identified genetic changes into clinical practice can bring improvement of prognosis assessment for children with ALL in Slovakia.
Links
EF16_013/0001818, research and development projectName: Modernizace a podpora výzkumných aktivit národní infrastruktury pro translační medicínu EATRIS-CZ
PrintDisplayed: 25/4/2024 12:20